Supplementary Figure 1. The overlap between statistically-significant and highconfidence

Size: px
Start display at page:

Download "Supplementary Figure 1. The overlap between statistically-significant and highconfidence"

Transcription

1 Supplementary figures Supplementary Figure 1. The overlap between statistically-significant and highconfidence PPIs with previously reported PPIs in public databases. Venn diagrams showing the overlap between SS-PPI and HC-PPI sets with PPIs previously reported in String, BioGrid, IntAct, and GeneMania reference PPI databases.

2 Supplementary Figure 2. Expansion of the PPI landscape for selected lung cancer genes. A heatmap representation of new PPI datasets (magenta OncoPPi PPIs, yellow SS-PPIs) showing expansion beyond the known cancer-associated PPI network (cyan are previously described PPIs).

3 Supplementary Figure 3. Heatmap showing integration of structural and localization data into the OncoPPi network. Known domains involved in co-crystallized PPI complexes indicated in magenta; potential interacting Pfam domains are indicated in cyan; co-localized PPIs are in purple, predicted co-localized PPIs are in orange.

4 Supplementary Figure 4. FUSION analysis of known PPIs involved in PI3K, RAS/ERK2, CDK4/RB, and Hippo pathways. Heatmaps show the expression of FUSION endogenous reporter genes (ACSL5, ALDOC, BNIP3, BNIP3L, LOXL2, NDRG1) obtained for individual gene knockouts. Blue and magenta colors indicate higher and lower expression, respectively. Pearson correlation values between the expression profiles of the reporter genes obtained for corresponding protein-protein pairs are shown.

5 Supplementary Figure 5. The OncoPPi network links tumor suppressors to actionable targets and cancer drugs. Connections between OncoPPi tumor suppressor genes (cyan), actionable cancer targets (pink circles) and further to FDA approved drugs (blue) or drugs in clinical trials (yellow) are indicated. Drug-target connections are indicated with red lines. Oncogene-tumor suppressor PPIs are indicated with black lines (Supplementary Table 5).

6 Supplementary Figure 6. STK11 expression correlates with response to CDK4 inhibitor palbociclib in the CCLE dataset. Twenty-two cell lines with reduced copy number of STK11 and normalized mrna RNAseq levels below 6, (STK11 Low), and 41 cell lines with no loss of STK11 DNA and normalized mrna RNAseq levels above 7 (STK11 High) were identified in the Cancer Cell Line Encyclopedia (CCLE) database. Analysis of the sensitivity to palbociclib for these two groups of cell lines indicated that those in the STK11 Low group had significantly greater palbociclib sensitivity (p = 0.002, two-sided T-test).

7 Supplementary Figure 7. Uncropped immunoblots for Figure 3b, c. Boxed areas correspond to images presented in the main text.

8 Supplementary Figure 8. Uncropped immunoblots for Figure 4b, c, d. Boxed areas correspond to images presented in the main text.

9 Supplementary Figure 9. Uncropped immunoblots for Figure 4f, g, j. Boxed areas correspond to images presented in the main text.

10 Supplementary Figure 10. Uncropped immunoblots for Figure 5e, f, g. Boxed areas correspond to images presented in the main text.

11 Supplementary Figure 11. Uncropped immunoblots for Figure 5h, i. Boxed areas correspond to images presented in the main text.

12 Supplementary Tables Supplementary Table 1. Characterization of nodes in the OncoPPi network, related to Figure 2 and 3. The table includes results from analysis of each node in the OncoPPI network, including the degree, number of novel PPI, numb er of known PPIs, total number of previously known PPIs, betweenness centrality, number of mutually exclusive PPI and number of PPI with functional connectivity through FUSION analysis. COMMON NAME HGNC DEGREE (TOTAL PPI) NOVEL PPI KNOWN PPI TOTAL NUMBER OF PREVIOUSLY KNOWN PPI BETWEENNESS CENTRALITY PPI SUPPORTED BY ME ANALYSIS PPI SUPOPRTED BY FUSION ANALYSIS MYC MYC NF2 NF AKT1 AKT EPHA2 EPHA FGFR4 FGFR STK11 STK CCND2 CCND CDK4 CDK LATS2 LATS MKK5 MAP2K CDK6 CDK MKK3 MAP2K CDKN2A CDKN2A CDKN2B CDKN2B RAF1 RAF RASSF1 RASSF GLIS2 GLIS HIF1-B ARNT KDELR2 KDELR ARAF ARAF PDGFRA PDGFRA BECN1 BECN

13 COMMON NAME HGNC DEGREE (TOTAL PPI) NOVEL PPI KNOWN PPI TOTAL NUMBER OF PREVIOUSLY KNOWN PPI BETWEENNESS CENTRALITY PPI SUPPORTED BY ME ANALYSIS PPI SUPOPRTED BY FUSION ANALYSIS FZR1 FZR AURKA AURKA ERBB2 ERBB CCNE1 CCNE TP53 TP GAMMA YWHAG CD44 CD TEAD2 TEAD GCN5 KAT2A ZETA YWHAZ BRAF BRAF GRM1 GRM MET MET TSC1 TSC TTYH2 TTYH CDKN2C CDKN2C DACH1 DACH HGF HGF P38 MAPK P65 RELA ASK1 MAP3K CBLC CBLC MKK6 MAP2K SOX3 SOX SOX4 SOX TCF3 TCF TERT TERT YAP1 YAP SIGMA SFN FOXO1 FOXO GLIS1 GLIS HIF1-A HIF1A H-RAS HRAS

14 COMMON NAME HGNC DEGREE (TOTAL PPI) NOVEL PPI KNOWN PPI TOTAL NUMBER OF PREVIOUSLY KNOWN PPI BETWEENNESS CENTRALITY PPI SUPPORTED BY ME ANALYSIS PPI SUPOPRTED BY FUSION ANALYSIS K-RAS KRAS MDM2 MDM MDM4 MDM MST1 STK MST2 STK SMARCA4 SMARCA WHSC1L1 WHSC1L ABCB5 ABCB MSH2 MSH PIK3R1 PIK3R PRAS40 AKT1S SMAD1 SMAD SMAD2 SMAD TNFRSF1A TNFRSF1A WT1 WT EGFR EGFR IGF1R IGF1R KEAP1 KEAP NFIC NFIC PIK3CA PIK3CA PTEN PTEN RB1 RB CBLB CBLB NA 0 0 CDC42 CDC NA 0 0 CTNNB1 CTNNB NA 0 0 E2F1 E2F NA 0 0 NF1 NF ROS1 ROS NA 0 0 COMMON NAME - Common protein name; HGNC - Standard HUGO gene symbol; DEGREE (TOTAL PPI) - Total number of PPIs; NOVEL PPI - The number of novel PPIs; KNOWN PPI - The number of previously reported PPI within the 83 tested proteins; TOTAL NUMBER OF PREVIOUSLY KNOWN PPI - Total number of previously reported PPIs; BETWEENNESS CENTRALITY - The Betwenness centrality index; PPI SUPPORTED BY ME ANALYSIS - The number of PPIs supported by mutual exclusivity of genomic alterations; PPI SUPOPRTED BY FUSION ANALYSIS - The number of PPIs supported by Fusion analysis.

15 Supplementary Table 2. Structural Pfam domains in OncoPPi proteins, related to Figure 2. The table includes a list of the structural domains extracted from Pfam for each node in the OncoPPi network. HGNC YWHAG SFN YWHAZ ABCB5 AKT1 ARAF MAP3K5 AURKA BECN1 BRAF CBLB CBLC CCND2 CCNE1 CD44 CDC42 CDK4 CDK6 CDKN2A CDKN2B CDKN2C CTNNB1 DACH1 E2F1 EGFR EPHA2 ERBB2 FGFR4 FOXO1 FZR1 KAT2A GLIS1 GLIS2 GRM1 Protein structural domains extracted from Pfam ; DUF722; DUF837; Orbi_VP5; SF3A2; Peptidase_C98; TPR_ ; DUF837; Peptidase_C98; TPR_ ; FliM; Peptidase_C98; TPR_12 ABC_tran; ABC_membrane; DUF2207 Pkinase_C; Pkinase; PH Pkinase_Tyr; C1_1; RBD; zf-ring-like Pkinase; DUF4071 Pkinase; MTBP_C APG6; BH3; FTA4; Exonuc_VII_L; HAUS-augmin3; LMBR1; ERM; Suppressor_APC; MT RBD; C1_1; zf-ring-like; Pkinase_Tyr Cbl_N; Cbl_N2; Cbl_N3; zf-c3hc4_3; UBA Cbl_N; Cbl_N2; Cbl_N3; SH2; zf-c3hc4_3 Cyclin_N; K-cyclin_vir_C; Cyclin_C Cyclin_N; Cyclin_C Xlink Ras; PET117 Pkinase Pkinase; Uricase Ank_5 Ank_5 DUF1843; Ank_4; Ank_5 HEAT_2; Queuosine_synth; Ric8; Arm; WAPL; Atx10homo_assoc Ski_Sno E2F_CC-MB; E2F_TDP Pkinase_Tyr; GF_recep_IV; Recep_L_domain; Furin-like; GAPT SAM_1; Pkinase_Tyr; EphA2_TM; fn3; Ephrin_lbd; GCC2_GCC3; DUF2369; SKG6 Pkinase_Tyr; GF_recep_IV; Recep_L_domain; Furin-like Pkinase_Tyr; I-set FOXO-TAD; FOXO_KIX_bdg; Forkhead WD40 Bromodomain; Acetyltransf_7; PCAF_N; T2SSM FOXP-CC; zf-h2c2_2; zf-c2h2 FOXP-CC; zf-h2c2_2; zf-c2h2 GluR_Homer-bdg; 7tm_3; NCD3G; ANF_receptor; AAA_34; DUF2318

16 HGNC HGF HIF1A ARNT HRAS IGF1R KDELR2 KEAP1 KRAS LATS2 MDM2 MDM4 MET MAP2K3 MAP2K5 MAP2K6 MSH2 STK4 STK3 MYC NF1 NF2 NFIC MAPK14 RELA PDGFRA PIK3CA PIK3R1 AKT1S1 PTEN RAF1 RASSF1 RB1 ROS1 SMAD1 SMAD2 SMARCA4 SOX3 SOX4 STK11 TCF3 TEAD2 Protein structural domains extracted from Pfam Trypsin; Kringle; PAN_1 HIF-1a_CTAD; HIF-1; PAS_3; PAS; HLH PAS_11; PAS; HLH; PRAS Ras; Ldh_1_N Pkinase_Tyr; Recep_L_domain; Furin-like; fn3; DUF4476 ER_lumen_recept Kelch_1; BACK; BTB Ras Pkinase; UBA; Pkinase_C zf-c3hc4_3; zf-ranbp; SWIB; Pinin_SDK_N; zf-fpg_ilers zf-c3hc4_3; zf-ranbp; SWIB; Cript; Cytochrom_c3_2 Pkinase_Tyr; TIG; PSI; Sema Pkinase; DUF4344; DHR-2 Pkinase; PB1 Pkinase; DUF4344 MutS_V; MutS_IV; MutS_III; MutS_II; MutS_I; ArdA Mst1_SARAH; Pkinase; Abi_2; DUF4611 Mst1_SARAH; Pkinase; Abi_2 Myc-LZ; HLH; Myc_N; TRH CRAL_TRIO_2; RasGAP; MIF4G_like_2; MOR2-PAG1_C ERM; FERM_C; FERM_M; FERM_N CTF_NFI; MH1; NfI_DNAbd_pre-N Pkinase; NAD_binding_8 RHD_dimer; RHD_DNA_bind Pkinase_Tyr; I-set; ig; Herpes_gE; LAT PF ; PF ; PF ; PF ; PF ; PI3K_p85B; PI3K_rbd; ASC; PI3K_C2; PI3Ka; DUF2321; Ribosomal_S15; PI3_PI4_kinase; DUF4135 SH2; PI3K_P85_iSH2; RhoGAP; SH3_2; Laminin_I; Lant_dehydr_C; Transcrip_act; Mod_r PRAS PTEN_C2; DSPc; DUF3256 Pkinase_Tyr; C1_1; RBD; zf-ring-like Nore1-SARAH; RA; C1_1; Mst1_SARAH Rb_C; RB_B; RB_A; DUF3452 fn3; Pkinase_Tyr MH2; MH1; DUF4223 MH1; MH2 QLQ; DUF2009; HSA; BRK; SNF2_N; Helicase_C; SnAC; Bromodomain SOXp; HMG_box HMG_box Pkinase HLH; CDC45; DUF4349 TEA

17 HGNC Protein structural domains extracted from Pfam TERT RVT_1; Telomerase_RBD TNFRSF1A Death; TNFR_c6 TP53 P53_tetramer; P53; P53_TAD TSC1 Hamartin TTYH2 Tweety; DUF4577; DUF4131 WHSC1L1 SET; PWWP; PHD; zf-hc5hc2h_2 WT1 zf-c2h2; Ofd1_CTDD; zf-h2c2_2; FOXP-CC YAP1 WW; FAM181; MbtH HGNC Standard HUGO gene symbol

18 Supplementary Table 3. Expression of FUSION reporter genes obtained for the individual gene knock downs, related to Figure 3, 5 and Supplementary Figure 4 The table includes the Pearson correlation values for mrna expression of each node in the OncoPPi network with the FUSION reporter genes (ACSL5, ALDOC, BNIP3, BNIP3L, LOXL2, NDRG1) based on large-scale profiling of individual gene knockdowns with sirna in HCT116 cells as described in Potts, et al, HGNC ACSL5 ALDOC BNIP3 BNIP3L LOXL2 NDRG1 MYC AKT RAF PDGFRA ARAF AURKA ERBB MET BRAF CBLC MDM HRAS KRAS WHSC1L TCF FOXO YAP PIK3CA EGFR CTNNB CBLB ROS NF STK LATS CDKN2B RASSF CDKN2A TSC TP SMARCA PIK3R WT RB PTEN SMAD

19 HGNC ACSL5 ALDOC BNIP3 BNIP3L LOXL2 NDRG1 MSH NF FGFR EPHA MAP2K CCND CDK CDK MAP2K GLIS ARNT KDELR BECN FZR CCNE TEAD CD GRM KAT2A CDKN2C DACH YWHAZ HGF MAP2K SOX SOX MAPK TERT SFN HIF1A AKT1S ABCB IGF1R MAP3K RELA MDM STK STK KEAP NFIC TNFRSF1A E2F SMAD CDC HGNC - Standard HUGO gene symbol

20 Supplementary Table 4. Correlations between expression signatures for microrna and OncoPPi genes, related to Figure 3, 5 and Supplementary Figure 4 The table includes a list of genes from FUSION analysis which have expression signatures that correlate with each node in the OncoPPi network. PPIs are scored as positive in FUSION analysis if the absolute value of the Pearson correlation coefficient (R) is greater than or equal to 0.5. ABCB5 APC ABCB5 BAX ABCB5 BCL ABCB5 CDC ABCB5 DVL ABCB5 E2F ABCB5 GSK3B ABCB5 IGF1R ABCB5 JAK ABCB5 JAK ABCB5 KEAP ABCB5 MAP2K ABCB5 MAP2K ABCB5 MAP3K ABCB5 MAPK ABCB5 MAPK ABCB5 MAPK ABCB5 MAPK ABCB5 MDM ABCB5 MTOR ABCB5 NFIC ABCB5 NFKB ABCB5 NOTCH ABCB5 PRKAA ABCB5 RELA ABCB5 SMAD ABCB5 SMAD ABCB5 STAT ABCB5 STAT ABCB5 STK ABCB5 STK ABCB5 TNFRSF1A AKT1 ABCB AKT1 AKT1S AKT1 APC AKT1 ARAF AKT1 ARNT AKT1 AURKA AKT1 BAX AKT1 BCL AKT1 BECN AKT1 BRAF AKT1 CBLB AKT1 CBLC AKT1 CCND AKT1 CCNE AKT1 CD AKT1 CDC AKT1 CDK AKT1 CDK AKT1 CDKN2A AKT1 CDKN2B AKT1 CDKN2C AKT1 CTNNB AKT1 DACH AKT1 DVL AKT1 E2F AKT1 EGFR AKT1 EPHA AKT1 ERBB AKT1 FGFR AKT1 FOXO AKT1 FZR AKT1 GLIS AKT1 GRM AKT1 GSK3B AKT1 HGF AKT1 HIF1A

21 AKT1 HRAS AKT1 IGF1R AKT1 JAK AKT1 JAK AKT1 KAT2A AKT1 KDELR AKT1 KEAP AKT1 KRAS AKT1 LATS AKT1 MAP2K AKT1 MAP2K AKT1 MAP2K AKT1 MAP2K AKT1 MAP2K AKT1 MAP3K AKT1 MAPK AKT1 MAPK AKT1 MAPK AKT1 MAPK AKT1 MAPK AKT1 MDM AKT1 MDM AKT1 MET AKT1 MSH AKT1 MTOR AKT1 NF AKT1 NF AKT1 NFIC AKT1 NFKB AKT1 NOTCH AKT1 PDGFRA AKT1 PIK3CA AKT1 PIK3R AKT1 PRKAA AKT1 PTEN AKT1 RAF AKT1 RASSF AKT1 RB AKT1 RELA AKT1 ROS AKT1 SFN AKT1 SMAD AKT1 SMAD AKT1 SMAD AKT1 SMARCA AKT1 SOX AKT1 SOX AKT1 STAT AKT1 STAT AKT1 STK AKT1 STK AKT1 STK AKT1 TCF AKT1 TEAD AKT1 TERT AKT1 TNFRSF1A AKT1 TP AKT1 TSC AKT1 WHSC1L AKT1 WT AKT1 YAP AKT1 YWHAZ AKT1S1 ABCB AKT1S1 APC AKT1S1 BAX AKT1S1 BCL AKT1S1 CDC AKT1S1 DVL AKT1S1 E2F AKT1S1 GSK3B AKT1S1 IGF1R AKT1S1 JAK AKT1S1 JAK AKT1S1 KEAP AKT1S1 MAP2K AKT1S1 MAP2K AKT1S1 MAP3K AKT1S1 MAPK AKT1S1 MAPK AKT1S1 MAPK AKT1S1 MAPK AKT1S1 MDM AKT1S1 MTOR AKT1S1 NFIC AKT1S1 NFKB AKT1S1 NOTCH AKT1S1 PRKAA AKT1S1 RELA AKT1S1 SMAD AKT1S1 SMAD AKT1S1 STAT AKT1S1 STAT AKT1S1 STK AKT1S1 STK AKT1S1 TNFRSF1A ARAF ABCB ARAF AKT1S ARAF APC

22 ARAF ARNT ARAF AURKA ARAF BAX ARAF BCL ARAF BECN ARAF BRAF ARAF CBLB ARAF CBLC ARAF CCND ARAF CCNE ARAF CD ARAF CDC ARAF CDK ARAF CDK ARAF CDKN2A ARAF CDKN2B ARAF CDKN2C ARAF CTNNB ARAF DACH ARAF DVL ARAF E2F ARAF EGFR ARAF EPHA ARAF ERBB ARAF FGFR ARAF FOXO ARAF FZR ARAF GLIS ARAF GRM ARAF GSK3B ARAF HGF ARAF HIF1A ARAF HRAS ARAF IGF1R ARAF JAK ARAF JAK ARAF KAT2A ARAF KDELR ARAF KEAP ARAF KRAS ARAF LATS ARAF MAP2K ARAF MAP2K ARAF MAP2K ARAF MAP2K ARAF MAP2K ARAF MAP3K ARAF MAPK ARAF MAPK ARAF MAPK ARAF MAPK ARAF MAPK ARAF MDM ARAF MDM ARAF MET ARAF MSH ARAF MTOR ARAF NF ARAF NF ARAF NFIC ARAF NFKB ARAF NOTCH ARAF PIK3CA ARAF PIK3R ARAF PRKAA ARAF PTEN ARAF RASSF ARAF RB ARAF RELA ARAF ROS ARAF SFN ARAF SMAD ARAF SMAD ARAF SMAD ARAF SMARCA ARAF SOX ARAF SOX ARAF STAT ARAF STAT ARAF STK ARAF STK ARAF STK ARAF TCF ARAF TEAD ARAF TERT ARAF TNFRSF1A ARAF TP ARAF TSC ARAF WHSC1L ARAF WT ARAF YAP ARAF YWHAZ ARNT ABCB ARNT AKT1S ARNT APC ARNT BAX ARNT BCL ARNT BECN

23 ARNT CCNE ARNT CD ARNT CDC ARNT CDKN2C ARNT DACH ARNT DVL ARNT E2F ARNT FZR ARNT GRM ARNT GSK3B ARNT HGF ARNT HIF1A ARNT IGF1R ARNT JAK ARNT JAK ARNT KAT2A ARNT KDELR ARNT KEAP ARNT MAP2K ARNT MAP2K ARNT MAP2K ARNT MAP3K ARNT MAPK ARNT MAPK ARNT MAPK ARNT MAPK ARNT MAPK ARNT MDM ARNT MTOR ARNT NFIC ARNT NFKB ARNT NOTCH ARNT PRKAA ARNT RELA ARNT SFN ARNT SMAD ARNT SMAD ARNT SOX ARNT SOX ARNT STAT ARNT STAT ARNT STK ARNT STK ARNT TEAD ARNT TERT ARNT TNFRSF1A ARNT YWHAZ AURKA ABCB AURKA AKT1S AURKA APC AURKA ARNT AURKA BAX AURKA BCL AURKA BECN AURKA BRAF AURKA CBLB AURKA CBLC AURKA CCND AURKA CCNE AURKA CD AURKA CDC AURKA CDK AURKA CDK AURKA CDKN2A AURKA CDKN2B AURKA CDKN2C AURKA CTNNB AURKA DACH AURKA DVL AURKA E2F AURKA EGFR AURKA EPHA AURKA ERBB AURKA FGFR AURKA FOXO AURKA FZR AURKA GLIS AURKA GRM AURKA GSK3B AURKA HGF AURKA HIF1A AURKA HRAS AURKA IGF1R AURKA JAK AURKA JAK AURKA KAT2A AURKA KDELR AURKA KEAP AURKA KRAS AURKA LATS AURKA MAP2K AURKA MAP2K AURKA MAP2K AURKA MAP2K AURKA MAP2K AURKA MAP3K AURKA MAPK AURKA MAPK

24 AURKA MAPK AURKA MAPK AURKA MAPK AURKA MDM AURKA MDM AURKA MET AURKA MSH AURKA MTOR AURKA NF AURKA NF AURKA NFIC AURKA NFKB AURKA NOTCH AURKA PIK3CA AURKA PIK3R AURKA PRKAA AURKA PTEN AURKA RASSF AURKA RB AURKA RELA AURKA ROS AURKA SFN AURKA SMAD AURKA SMAD AURKA SMAD AURKA SMARCA AURKA SOX AURKA SOX AURKA STAT AURKA STAT AURKA STK AURKA STK AURKA STK AURKA TCF AURKA TEAD AURKA TERT AURKA TNFRSF1A AURKA TP AURKA TSC AURKA WHSC1L AURKA WT AURKA YAP AURKA YWHAZ BECN1 ABCB BECN1 AKT1S BECN1 APC BECN1 BAX BECN1 BCL BECN1 CCNE BECN1 CD BECN1 CDC BECN1 CDKN2C BECN1 DACH BECN1 DVL BECN1 E2F BECN1 FZR BECN1 GRM BECN1 GSK3B BECN1 HGF BECN1 HIF1A BECN1 IGF1R BECN1 JAK BECN1 JAK BECN1 KAT2A BECN1 KEAP BECN1 MAP2K BECN1 MAP2K BECN1 MAP2K BECN1 MAP3K BECN1 MAPK BECN1 MAPK BECN1 MAPK BECN1 MAPK BECN1 MAPK BECN1 MDM BECN1 MTOR BECN1 NFIC BECN1 NFKB BECN1 NOTCH BECN1 PRKAA BECN1 RELA BECN1 SFN BECN1 SMAD BECN1 SMAD BECN1 SOX BECN1 SOX BECN1 STAT BECN1 STAT BECN1 STK BECN1 STK BECN1 TEAD BECN1 TERT BECN1 TNFRSF1A BECN1 YWHAZ BRAF ABCB BRAF AKT1S BRAF APC BRAF ARNT

25 BRAF BAX BRAF BCL BRAF BECN BRAF CBLB BRAF CBLC BRAF CCND BRAF CCNE BRAF CD BRAF CDC BRAF CDK BRAF CDK BRAF CDKN2A BRAF CDKN2B BRAF CDKN2C BRAF CTNNB BRAF DACH BRAF DVL BRAF E2F BRAF EGFR BRAF EPHA BRAF FGFR BRAF FOXO BRAF FZR BRAF GLIS BRAF GRM BRAF GSK3B BRAF HGF BRAF HIF1A BRAF HRAS BRAF IGF1R BRAF JAK BRAF JAK BRAF KAT2A BRAF KDELR BRAF KEAP BRAF KRAS BRAF LATS BRAF MAP2K BRAF MAP2K BRAF MAP2K BRAF MAP2K BRAF MAP2K BRAF MAP3K BRAF MAPK BRAF MAPK BRAF MAPK BRAF MAPK BRAF MAPK BRAF MDM BRAF MDM BRAF MSH BRAF MTOR BRAF NF BRAF NF BRAF NFIC BRAF NFKB BRAF NOTCH BRAF PIK3CA BRAF PIK3R BRAF PRKAA BRAF PTEN BRAF RASSF BRAF RB BRAF RELA BRAF ROS BRAF SFN BRAF SMAD BRAF SMAD BRAF SMAD BRAF SMARCA BRAF SOX BRAF SOX BRAF STAT BRAF STAT BRAF STK BRAF STK BRAF STK BRAF TCF BRAF TEAD BRAF TERT BRAF TNFRSF1A BRAF TP BRAF TSC BRAF WHSC1L BRAF WT BRAF YAP BRAF YWHAZ CBLB ABCB CBLB AKT1S CBLB APC CBLB ARNT CBLB BAX CBLB BCL CBLB BECN CBLB CCND CBLB CCNE CBLB CD CBLB CDC

26 CBLB CDK CBLB CDK CBLB CDKN2A CBLB CDKN2B CBLB CDKN2C CBLB DACH CBLB DVL CBLB E2F CBLB EPHA CBLB FGFR CBLB FZR CBLB GLIS CBLB GRM CBLB GSK3B CBLB HGF CBLB HIF1A CBLB IGF1R CBLB JAK CBLB JAK CBLB KAT2A CBLB KDELR CBLB KEAP CBLB LATS CBLB MAP2K CBLB MAP2K CBLB MAP2K CBLB MAP2K CBLB MAP2K CBLB MAP3K CBLB MAPK CBLB MAPK CBLB MAPK CBLB MAPK CBLB MAPK CBLB MDM CBLB MSH CBLB MTOR CBLB NF CBLB NF CBLB NFIC CBLB NFKB CBLB NOTCH CBLB PIK3R CBLB PRKAA CBLB PTEN CBLB RASSF CBLB RB CBLB RELA CBLB ROS CBLB SFN CBLB SMAD CBLB SMAD CBLB SMAD CBLB SMARCA CBLB SOX CBLB SOX CBLB STAT CBLB STAT CBLB STK CBLB STK CBLB STK CBLB TEAD CBLB TERT CBLB TNFRSF1A CBLB TP CBLB TSC CBLB WT CBLB YWHAZ CBLC ABCB CBLC AKT1S CBLC APC CBLC ARNT CBLC BAX CBLC BCL CBLC BECN CBLC CBLB CBLC CCND CBLC CCNE CBLC CD CBLC CDC CBLC CDK CBLC CDK CBLC CDKN2A CBLC CDKN2B CBLC CDKN2C CBLC CTNNB CBLC DACH CBLC DVL CBLC E2F CBLC EGFR CBLC EPHA CBLC FGFR CBLC FOXO CBLC FZR CBLC GLIS CBLC GRM CBLC GSK3B CBLC HGF

27 CBLC HIF1A CBLC HRAS CBLC IGF1R CBLC JAK CBLC JAK CBLC KAT2A CBLC KDELR CBLC KEAP CBLC KRAS CBLC LATS CBLC MAP2K CBLC MAP2K CBLC MAP2K CBLC MAP2K CBLC MAP2K CBLC MAP3K CBLC MAPK CBLC MAPK CBLC MAPK CBLC MAPK CBLC MAPK CBLC MDM CBLC MDM CBLC MSH CBLC MTOR CBLC NF CBLC NF CBLC NFIC CBLC NFKB CBLC NOTCH CBLC PIK3CA CBLC PIK3R CBLC PRKAA CBLC PTEN CBLC RASSF CBLC RB CBLC RELA CBLC ROS CBLC SFN CBLC SMAD CBLC SMAD CBLC SMAD CBLC SMARCA CBLC SOX CBLC SOX CBLC STAT CBLC STAT CBLC STK CBLC STK CBLC STK CBLC TCF CBLC TEAD CBLC TERT CBLC TNFRSF1A CBLC TP CBLC TSC CBLC WHSC1L CBLC WT CBLC YAP CBLC YWHAZ CCND2 ABCB CCND2 AKT1S CCND2 APC CCND2 ARNT CCND2 BAX CCND2 BCL CCND2 BECN CCND2 CCNE CCND2 CD CCND2 CDC CCND2 CDK CCND2 CDK CCND2 CDKN2C CCND2 DACH CCND2 DVL CCND2 E2F CCND2 FZR CCND2 GLIS CCND2 GRM CCND2 GSK3B CCND2 HGF CCND2 HIF1A CCND2 IGF1R CCND2 JAK CCND2 JAK CCND2 KAT2A CCND2 KDELR CCND2 KEAP CCND2 MAP2K CCND2 MAP2K CCND2 MAP2K CCND2 MAP2K CCND2 MAP3K CCND2 MAPK CCND2 MAPK CCND2 MAPK CCND2 MAPK CCND2 MAPK

28 CCND2 MDM CCND2 MTOR CCND2 NFIC CCND2 NFKB CCND2 NOTCH CCND2 PRKAA CCND2 RELA CCND2 SFN CCND2 SMAD CCND2 SMAD CCND2 SOX CCND2 SOX CCND2 STAT CCND2 STAT CCND2 STK CCND2 STK CCND2 TEAD CCND2 TERT CCND2 TNFRSF1A CCND2 YWHAZ CCNE1 ABCB CCNE1 AKT1S CCNE1 APC CCNE1 BAX CCNE1 BCL CCNE1 CD CCNE1 CDC CCNE1 CDKN2C CCNE1 DACH CCNE1 DVL CCNE1 E2F CCNE1 GRM CCNE1 GSK3B CCNE1 HGF CCNE1 HIF1A CCNE1 IGF1R CCNE1 JAK CCNE1 JAK CCNE1 KAT2A CCNE1 KEAP CCNE1 MAP2K CCNE1 MAP2K CCNE1 MAP2K CCNE1 MAP3K CCNE1 MAPK CCNE1 MAPK CCNE1 MAPK CCNE1 MAPK CCNE1 MAPK CCNE1 MDM CCNE1 MTOR CCNE1 NFIC CCNE1 NFKB CCNE1 NOTCH CCNE1 PRKAA CCNE1 RELA CCNE1 SFN CCNE1 SMAD CCNE1 SMAD CCNE1 SOX CCNE1 SOX CCNE1 STAT CCNE1 STAT CCNE1 STK CCNE1 STK CCNE1 TEAD CCNE1 TERT CCNE1 TNFRSF1A CCNE1 YWHAZ CD44 ABCB CD44 AKT1S CD44 APC CD44 BAX CD44 BCL CD44 CDC CD44 CDKN2C CD44 DACH CD44 DVL CD44 E2F CD44 GRM CD44 GSK3B CD44 HGF CD44 HIF1A CD44 IGF1R CD44 JAK CD44 JAK CD44 KAT2A CD44 KEAP CD44 MAP2K CD44 MAP2K CD44 MAP2K CD44 MAP3K CD44 MAPK CD44 MAPK CD44 MAPK CD44 MAPK CD44 MAPK CD44 MDM

29 CD44 MTOR CD44 NFIC CD44 NFKB CD44 NOTCH CD44 PRKAA CD44 RELA CD44 SFN CD44 SMAD CD44 SMAD CD44 SOX CD44 SOX CD44 STAT CD44 STAT CD44 STK CD44 STK CD44 TERT CD44 TNFRSF1A CD44 YWHAZ CDC42 APC CDC42 BAX CDC42 BCL CDC42 DVL CDC42 GSK3B CDC42 JAK CDC42 JAK CDC42 MAP2K CDC42 MAP2K CDC42 MAPK CDC42 MAPK CDC42 MAPK CDC42 MAPK CDC42 MTOR CDC42 NFKB CDC42 NOTCH CDC42 PRKAA CDC42 SMAD CDC42 STAT CDC42 STAT CDK4 ABCB CDK4 AKT1S CDK4 APC CDK4 ARNT CDK4 BAX CDK4 BCL CDK4 BECN CDK4 CCNE CDK4 CD CDK4 CDC CDK4 CDKN2C CDK4 DACH CDK4 DVL CDK4 E2F CDK4 FZR CDK4 GLIS CDK4 GRM CDK4 GSK3B CDK4 HGF CDK4 HIF1A CDK4 IGF1R CDK4 JAK CDK4 JAK CDK4 KAT2A CDK4 KDELR CDK4 KEAP CDK4 MAP2K CDK4 MAP2K CDK4 MAP2K CDK4 MAP2K CDK4 MAP3K CDK4 MAPK CDK4 MAPK CDK4 MAPK CDK4 MAPK CDK4 MAPK CDK4 MDM CDK4 MTOR CDK4 NFIC CDK4 NFKB CDK4 NOTCH CDK4 PRKAA CDK4 RELA CDK4 SFN CDK4 SMAD CDK4 SMAD CDK4 SOX CDK4 SOX CDK4 STAT CDK4 STAT CDK4 STK CDK4 STK CDK4 TEAD CDK4 TERT CDK4 TNFRSF1A CDK4 YWHAZ CDK6 ABCB CDK6 AKT1S CDK6 APC CDK6 ARNT

30 CDK6 BAX CDK6 BCL CDK6 BECN CDK6 CCNE CDK6 CD CDK6 CDC CDK6 CDK CDK6 CDKN2C CDK6 DACH CDK6 DVL CDK6 E2F CDK6 FZR CDK6 GLIS CDK6 GRM CDK6 GSK3B CDK6 HGF CDK6 HIF1A CDK6 IGF1R CDK6 JAK CDK6 JAK CDK6 KAT2A CDK6 KDELR CDK6 KEAP CDK6 MAP2K CDK6 MAP2K CDK6 MAP2K CDK6 MAP2K CDK6 MAP3K CDK6 MAPK CDK6 MAPK CDK6 MAPK CDK6 MAPK CDK6 MAPK CDK6 MDM CDK6 MTOR CDK6 NFIC CDK6 NFKB CDK6 NOTCH CDK6 PRKAA CDK6 RELA CDK6 SFN CDK6 SMAD CDK6 SMAD CDK6 SOX CDK6 SOX CDK6 STAT CDK6 STAT CDK6 STK CDK6 STK CDK6 TEAD CDK6 TERT CDK6 TNFRSF1A CDK6 YWHAZ CDKN2A ABCB CDKN2A AKT1S CDKN2A APC CDKN2A ARNT CDKN2A BAX CDKN2A BCL CDKN2A BECN CDKN2A CCND CDKN2A CCNE CDKN2A CD CDKN2A CDC CDKN2A CDK CDKN2A CDK CDKN2A CDKN2C CDKN2A DACH CDKN2A DVL CDKN2A E2F CDKN2A EPHA CDKN2A FGFR CDKN2A FZR CDKN2A GLIS CDKN2A GRM CDKN2A GSK3B CDKN2A HGF CDKN2A HIF1A CDKN2A IGF1R CDKN2A JAK CDKN2A JAK CDKN2A KAT2A CDKN2A KDELR CDKN2A KEAP CDKN2A MAP2K CDKN2A MAP2K CDKN2A MAP2K CDKN2A MAP2K CDKN2A MAP2K CDKN2A MAP3K CDKN2A MAPK CDKN2A MAPK CDKN2A MAPK CDKN2A MAPK CDKN2A MAPK CDKN2A MDM CDKN2A MSH CDKN2A MTOR

31 CDKN2A NF CDKN2A NFIC CDKN2A NFKB CDKN2A NOTCH CDKN2A PIK3R CDKN2A PRKAA CDKN2A PTEN CDKN2A RB CDKN2A RELA CDKN2A SFN CDKN2A SMAD CDKN2A SMAD CDKN2A SMAD CDKN2A SMARCA CDKN2A SOX CDKN2A SOX CDKN2A STAT CDKN2A STAT CDKN2A STK CDKN2A STK CDKN2A TEAD CDKN2A TERT CDKN2A TNFRSF1A CDKN2A TP CDKN2A TSC CDKN2A WT CDKN2A YWHAZ CDKN2B ABCB CDKN2B AKT1S CDKN2B APC CDKN2B ARNT CDKN2B BAX CDKN2B BCL CDKN2B BECN CDKN2B CCND CDKN2B CCNE CDKN2B CD CDKN2B CDC CDKN2B CDK CDKN2B CDK CDKN2B CDKN2A CDKN2B CDKN2C CDKN2B DACH CDKN2B DVL CDKN2B E2F CDKN2B EPHA CDKN2B FGFR CDKN2B FZR CDKN2B GLIS CDKN2B GRM CDKN2B GSK3B CDKN2B HGF CDKN2B HIF1A CDKN2B IGF1R CDKN2B JAK CDKN2B JAK CDKN2B KAT2A CDKN2B KDELR CDKN2B KEAP CDKN2B MAP2K CDKN2B MAP2K CDKN2B MAP2K CDKN2B MAP2K CDKN2B MAP2K CDKN2B MAP3K CDKN2B MAPK CDKN2B MAPK CDKN2B MAPK CDKN2B MAPK CDKN2B MAPK CDKN2B MDM CDKN2B MSH CDKN2B MTOR CDKN2B NF CDKN2B NFIC CDKN2B NFKB CDKN2B NOTCH CDKN2B PIK3R CDKN2B PRKAA CDKN2B PTEN CDKN2B RASSF CDKN2B RB CDKN2B RELA CDKN2B SFN CDKN2B SMAD CDKN2B SMAD CDKN2B SMAD CDKN2B SMARCA CDKN2B SOX CDKN2B SOX CDKN2B STAT CDKN2B STAT CDKN2B STK CDKN2B STK CDKN2B TEAD CDKN2B TERT CDKN2B TNFRSF1A CDKN2B TP

32 CDKN2B TSC CDKN2B WT CDKN2B YWHAZ CDKN2C ABCB CDKN2C AKT1S CDKN2C APC CDKN2C BAX CDKN2C BCL CDKN2C CDC CDKN2C DACH CDKN2C DVL CDKN2C E2F CDKN2C GSK3B CDKN2C HGF CDKN2C HIF1A CDKN2C IGF1R CDKN2C JAK CDKN2C JAK CDKN2C KEAP CDKN2C MAP2K CDKN2C MAP2K CDKN2C MAP2K CDKN2C MAP3K CDKN2C MAPK CDKN2C MAPK CDKN2C MAPK CDKN2C MAPK CDKN2C MAPK CDKN2C MDM CDKN2C MTOR CDKN2C NFIC CDKN2C NFKB CDKN2C NOTCH CDKN2C PRKAA CDKN2C RELA CDKN2C SFN CDKN2C SMAD CDKN2C SMAD CDKN2C SOX CDKN2C SOX CDKN2C STAT CDKN2C STAT CDKN2C STK CDKN2C STK CDKN2C TERT CDKN2C TNFRSF1A CDKN2C YWHAZ CTNNB1 ABCB CTNNB1 AKT1S CTNNB1 APC CTNNB1 ARNT CTNNB1 BAX CTNNB1 BCL CTNNB1 BECN CTNNB1 CBLB CTNNB1 CCND CTNNB1 CCNE CTNNB1 CD CTNNB1 CDC CTNNB1 CDK CTNNB1 CDK CTNNB1 CDKN2A CTNNB1 CDKN2B CTNNB1 CDKN2C CTNNB1 DACH CTNNB1 DVL CTNNB1 E2F CTNNB1 EPHA CTNNB1 FGFR CTNNB1 FZR CTNNB1 GLIS CTNNB1 GRM CTNNB1 GSK3B CTNNB1 HGF CTNNB1 HIF1A CTNNB1 IGF1R CTNNB1 JAK CTNNB1 JAK CTNNB1 KAT2A CTNNB1 KDELR CTNNB1 KEAP CTNNB1 LATS CTNNB1 MAP2K CTNNB1 MAP2K CTNNB1 MAP2K CTNNB1 MAP2K CTNNB1 MAP2K CTNNB1 MAP3K CTNNB1 MAPK CTNNB1 MAPK CTNNB1 MAPK CTNNB1 MAPK CTNNB1 MAPK CTNNB1 MDM CTNNB1 MSH CTNNB1 MTOR CTNNB1 NF CTNNB1 NF

33 CTNNB1 NFIC CTNNB1 NFKB CTNNB1 NOTCH CTNNB1 PIK3R CTNNB1 PRKAA CTNNB1 PTEN CTNNB1 RASSF CTNNB1 RB CTNNB1 RELA CTNNB1 ROS CTNNB1 SFN CTNNB1 SMAD CTNNB1 SMAD CTNNB1 SMAD CTNNB1 SMARCA CTNNB1 SOX CTNNB1 SOX CTNNB1 STAT CTNNB1 STAT CTNNB1 STK CTNNB1 STK CTNNB1 STK CTNNB1 TEAD CTNNB1 TERT CTNNB1 TNFRSF1A CTNNB1 TP CTNNB1 TSC CTNNB1 WT CTNNB1 YWHAZ DACH1 ABCB DACH1 AKT1S DACH1 APC DACH1 BAX DACH1 BCL DACH1 CDC DACH1 DVL DACH1 E2F DACH1 GSK3B DACH1 HGF DACH1 HIF1A DACH1 IGF1R DACH1 JAK DACH1 JAK DACH1 KEAP DACH1 MAP2K DACH1 MAP2K DACH1 MAP2K DACH1 MAP3K DACH1 MAPK DACH1 MAPK DACH1 MAPK DACH1 MAPK DACH1 MAPK DACH1 MDM DACH1 MTOR DACH1 NFIC DACH1 NFKB DACH1 NOTCH DACH1 PRKAA DACH1 RELA DACH1 SFN DACH1 SMAD DACH1 SMAD DACH1 SOX DACH1 SOX DACH1 STAT DACH1 STAT DACH1 STK DACH1 STK DACH1 TERT DACH1 TNFRSF1A DACH1 YWHAZ E2F1 APC E2F1 BAX E2F1 BCL E2F1 CDC E2F1 DVL E2F1 GSK3B E2F1 JAK E2F1 JAK E2F1 MAP2K E2F1 MAP2K E2F1 MAPK E2F1 MAPK E2F1 MAPK E2F1 MAPK E2F1 MTOR E2F1 NFKB E2F1 NOTCH E2F1 PRKAA E2F1 SMAD E2F1 SMAD E2F1 STAT E2F1 STAT EGFR ABCB EGFR AKT1S EGFR APC EGFR ARNT

34 EGFR BAX EGFR BCL EGFR BECN EGFR CBLB EGFR CCND EGFR CCNE EGFR CD EGFR CDC EGFR CDK EGFR CDK EGFR CDKN2A EGFR CDKN2B EGFR CDKN2C EGFR CTNNB EGFR DACH EGFR DVL EGFR E2F EGFR EPHA EGFR FGFR EGFR FZR EGFR GLIS EGFR GRM EGFR GSK3B EGFR HGF EGFR HIF1A EGFR IGF1R EGFR JAK EGFR JAK EGFR KAT2A EGFR KDELR EGFR KEAP EGFR LATS EGFR MAP2K EGFR MAP2K EGFR MAP2K EGFR MAP2K EGFR MAP2K EGFR MAP3K EGFR MAPK EGFR MAPK EGFR MAPK EGFR MAPK EGFR MAPK EGFR MDM EGFR MSH EGFR MTOR EGFR NF EGFR NF EGFR NFIC EGFR NFKB EGFR NOTCH EGFR PIK3R EGFR PRKAA EGFR PTEN EGFR RASSF EGFR RB EGFR RELA EGFR ROS EGFR SFN EGFR SMAD EGFR SMAD EGFR SMAD EGFR SMARCA EGFR SOX EGFR SOX EGFR STAT EGFR STAT EGFR STK EGFR STK EGFR STK EGFR TEAD EGFR TERT EGFR TNFRSF1A EGFR TP EGFR TSC EGFR WT EGFR YWHAZ EPHA2 ABCB EPHA2 AKT1S EPHA2 APC EPHA2 ARNT EPHA2 BAX EPHA2 BCL EPHA2 BECN EPHA2 CCND EPHA2 CCNE EPHA2 CD EPHA2 CDC EPHA2 CDK EPHA2 CDK EPHA2 CDKN2C EPHA2 DACH EPHA2 DVL EPHA2 E2F EPHA2 FZR EPHA2 GLIS EPHA2 GRM EPHA2 GSK3B

35 EPHA2 HGF EPHA2 HIF1A EPHA2 IGF1R EPHA2 JAK EPHA2 JAK EPHA2 KAT2A EPHA2 KDELR EPHA2 KEAP EPHA2 MAP2K EPHA2 MAP2K EPHA2 MAP2K EPHA2 MAP2K EPHA2 MAP2K EPHA2 MAP3K EPHA2 MAPK EPHA2 MAPK EPHA2 MAPK EPHA2 MAPK EPHA2 MAPK EPHA2 MDM EPHA2 MTOR EPHA2 NFIC EPHA2 NFKB EPHA2 NOTCH EPHA2 PRKAA EPHA2 RELA EPHA2 SFN EPHA2 SMAD EPHA2 SMAD EPHA2 SOX EPHA2 SOX EPHA2 STAT EPHA2 STAT EPHA2 STK EPHA2 STK EPHA2 TEAD EPHA2 TERT EPHA2 TNFRSF1A EPHA2 YWHAZ ERBB2 ABCB ERBB2 AKT1S ERBB2 APC ERBB2 ARNT ERBB2 BAX ERBB2 BCL ERBB2 BECN ERBB2 BRAF ERBB2 CBLB ERBB2 CBLC ERBB2 CCND ERBB2 CCNE ERBB2 CD ERBB2 CDC ERBB2 CDK ERBB2 CDK ERBB2 CDKN2A ERBB2 CDKN2B ERBB2 CDKN2C ERBB2 CTNNB ERBB2 DACH ERBB2 DVL ERBB2 E2F ERBB2 EGFR ERBB2 EPHA ERBB2 FGFR ERBB2 FOXO ERBB2 FZR ERBB2 GLIS ERBB2 GRM ERBB2 GSK3B ERBB2 HGF ERBB2 HIF1A ERBB2 HRAS ERBB2 IGF1R ERBB2 JAK ERBB2 JAK ERBB2 KAT2A ERBB2 KDELR ERBB2 KEAP ERBB2 KRAS ERBB2 LATS ERBB2 MAP2K ERBB2 MAP2K ERBB2 MAP2K ERBB2 MAP2K ERBB2 MAP2K ERBB2 MAP3K ERBB2 MAPK ERBB2 MAPK ERBB2 MAPK ERBB2 MAPK ERBB2 MAPK ERBB2 MDM ERBB2 MDM ERBB2 MET ERBB2 MSH ERBB2 MTOR ERBB2 NF

36 ERBB2 NF ERBB2 NFIC ERBB2 NFKB ERBB2 NOTCH ERBB2 PIK3CA ERBB2 PIK3R ERBB2 PRKAA ERBB2 PTEN ERBB2 RASSF ERBB2 RB ERBB2 RELA ERBB2 ROS ERBB2 SFN ERBB2 SMAD ERBB2 SMAD ERBB2 SMAD ERBB2 SMARCA ERBB2 SOX ERBB2 SOX ERBB2 STAT ERBB2 STAT ERBB2 STK ERBB2 STK ERBB2 STK ERBB2 TCF ERBB2 TEAD ERBB2 TERT ERBB2 TNFRSF1A ERBB2 TP ERBB2 TSC ERBB2 WHSC1L ERBB2 WT ERBB2 YAP ERBB2 YWHAZ FGFR4 ABCB FGFR4 AKT1S FGFR4 APC FGFR4 ARNT FGFR4 BAX FGFR4 BCL FGFR4 BECN FGFR4 CCND FGFR4 CCNE FGFR4 CD FGFR4 CDC FGFR4 CDK FGFR4 CDK FGFR4 CDKN2C FGFR4 DACH FGFR4 DVL FGFR4 E2F FGFR4 EPHA FGFR4 FZR FGFR4 GLIS FGFR4 GRM FGFR4 GSK3B FGFR4 HGF FGFR4 HIF1A FGFR4 IGF1R FGFR4 JAK FGFR4 JAK FGFR4 KAT2A FGFR4 KDELR FGFR4 KEAP FGFR4 MAP2K FGFR4 MAP2K FGFR4 MAP2K FGFR4 MAP2K FGFR4 MAP2K FGFR4 MAP3K FGFR4 MAPK FGFR4 MAPK FGFR4 MAPK FGFR4 MAPK FGFR4 MAPK FGFR4 MDM FGFR4 MTOR FGFR4 NFIC FGFR4 NFKB FGFR4 NOTCH FGFR4 PRKAA FGFR4 RELA FGFR4 SFN FGFR4 SMAD FGFR4 SMAD FGFR4 SOX FGFR4 SOX FGFR4 STAT FGFR4 STAT FGFR4 STK FGFR4 STK FGFR4 TEAD FGFR4 TERT FGFR4 TNFRSF1A FGFR4 YWHAZ FOXO1 ABCB FOXO1 AKT1S FOXO1 APC

37 FOXO1 ARNT FOXO1 BAX FOXO1 BCL FOXO1 BECN FOXO1 CBLB FOXO1 CCND FOXO1 CCNE FOXO1 CD FOXO1 CDC FOXO1 CDK FOXO1 CDK FOXO1 CDKN2A FOXO1 CDKN2B FOXO1 CDKN2C FOXO1 CTNNB FOXO1 DACH FOXO1 DVL FOXO1 E2F FOXO1 EGFR FOXO1 EPHA FOXO1 FGFR FOXO1 FZR FOXO1 GLIS FOXO1 GRM FOXO1 GSK3B FOXO1 HGF FOXO1 HIF1A FOXO1 IGF1R FOXO1 JAK FOXO1 JAK FOXO1 KAT2A FOXO1 KDELR FOXO1 KEAP FOXO1 LATS FOXO1 MAP2K FOXO1 MAP2K FOXO1 MAP2K FOXO1 MAP2K FOXO1 MAP2K FOXO1 MAP3K FOXO1 MAPK FOXO1 MAPK FOXO1 MAPK FOXO1 MAPK FOXO1 MAPK FOXO1 MDM FOXO1 MSH FOXO1 MTOR FOXO1 NF FOXO1 NF FOXO1 NFIC FOXO1 NFKB FOXO1 NOTCH FOXO1 PIK3CA FOXO1 PIK3R FOXO1 PRKAA FOXO1 PTEN FOXO1 RASSF FOXO1 RB FOXO1 RELA FOXO1 ROS FOXO1 SFN FOXO1 SMAD FOXO1 SMAD FOXO1 SMAD FOXO1 SMARCA FOXO1 SOX FOXO1 SOX FOXO1 STAT FOXO1 STAT FOXO1 STK FOXO1 STK FOXO1 STK FOXO1 TEAD FOXO1 TERT FOXO1 TNFRSF1A FOXO1 TP FOXO1 TSC FOXO1 WT FOXO1 YAP FOXO1 YWHAZ FZR1 ABCB FZR1 AKT1S FZR1 APC FZR1 BAX FZR1 BCL FZR1 CCNE FZR1 CD FZR1 CDC FZR1 CDKN2C FZR1 DACH FZR1 DVL FZR1 E2F FZR1 GRM FZR1 GSK3B FZR1 HGF FZR1 HIF1A FZR1 IGF1R

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018 Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations

More information

Clinical Grade Genomic Profiling: The Time Has Come

Clinical Grade Genomic Profiling: The Time Has Come Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation

More information

What is the status of the technologies of "precision medicine?

What is the status of the technologies of precision medicine? Session 2: What is the status of the technologies of "precision medicine? Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, Center for Drug Evaluation and Research (CDER), U.S.

More information

SureSelect Cancer All-In-One Custom and Catalog NGS Assays

SureSelect Cancer All-In-One Custom and Catalog NGS Assays SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis

More information

Supplementary Figure 1. Copy Number Alterations TP53 Mutation Type. C-class TP53 WT. TP53 mut. Nature Genetics: doi: /ng.

Supplementary Figure 1. Copy Number Alterations TP53 Mutation Type. C-class TP53 WT. TP53 mut. Nature Genetics: doi: /ng. Supplementary Figure a Copy Number Alterations in M-class b TP53 Mutation Type Recurrent Copy Number Alterations 8 6 4 2 TP53 WT TP53 mut TP53-mutated samples (%) 7 6 5 4 3 2 Missense Truncating M-class

More information

Jennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA

Jennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA Comparison of Genomic Coverage using Affymetrix OncoScan Array and Illumina TruSight Tumor 170 NGS Panel for Detection of Copy Number Abnormalities in Clinical GBM Specimens Jennifer Hauenstein Oncology

More information

Plasma-Seq conducted with blood from male individuals without cancer.

Plasma-Seq conducted with blood from male individuals without cancer. Supplementary Figures Supplementary Figure 1 Plasma-Seq conducted with blood from male individuals without cancer. Copy number patterns established from plasma samples of male individuals without cancer

More information

OncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies

OncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies OncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies 2017 Contents Datasets... 2 Protein-protein interaction dataset... 2 Set of known PPIs... 3 Domain-domain interactions...

More information

Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD

Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD Neuropathology Fellow Division of Neuropathology Center for Personalized Diagnosis (CPD) Glial

More information

Assessing the Economics of Genomic Medicine. Kenneth Offit, MD MPH Chief, Clinical Genetics Service Memorial Sloan-Kettering Cancer Center

Assessing the Economics of Genomic Medicine. Kenneth Offit, MD MPH Chief, Clinical Genetics Service Memorial Sloan-Kettering Cancer Center Assessing the Economics of Genomic Medicine Kenneth Offit, MD MPH Chief, Clinical Genetics Service Memorial Sloan-Kettering Cancer Center DISCLOSURES No conflicts Patents unenforced Consultancies unpaid

More information

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram

More information

Jocelyn Chapman, MD Division of Gynecologic Oncology. Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic

Jocelyn Chapman, MD Division of Gynecologic Oncology. Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic Jocelyn Chapman, MD Division of Gynecologic Oncology Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic Genetics underlies all cancers Somatic or tumor genetics Germline or inherited genetics

More information

Looking Beyond the Standard-of- Care : The Clinical Trial Option

Looking Beyond the Standard-of- Care : The Clinical Trial Option 1 Looking Beyond the Standard-of- Care : The Clinical Trial Option Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor

More information

Precision Oncology: Experience at UW

Precision Oncology: Experience at UW Precision Oncology: Experience at UW Colin Pritchard MD, PhD University of Washington, Department of Lab Medicine WSMOS Meeting November 1, 2013 Conflict of Interest Disclosures I declare the following,

More information

Illumina s Cancer Research Portfolio and Dedicated Workflows

Illumina s Cancer Research Portfolio and Dedicated Workflows Illumina s Cancer Research Portfolio and Dedicated Workflows Michael Sohn Clinical Sales Specialist Spain&Italy 2017 2017 Illumina, Inc. All rights reserved. Illumina, 24sure, BaseSpace, BeadArray, BlueFish,

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION Frampton et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing Supplementary Figure 1A Base substitution detection

More information

Nature Genetics: doi: /ng Supplementary Figure 1. Depths and coverages in whole-exome and targeted deep sequencing data.

Nature Genetics: doi: /ng Supplementary Figure 1. Depths and coverages in whole-exome and targeted deep sequencing data. Supplementary Figure 1 Depths and coverages in whole-exome and targeted deep sequencing data. Depth (top) and coverage (bottom) of whole-exome sequencing for 38 independent JPN cases (mean depth = 130)

More information

Case Study - Informatics

Case Study - Informatics bd@jubilantbiosys.com Case Study - Informatics www.jubilantbiosys.com Validating as a Prognostic marker and Therapeutic Target for Multiple Cancers Introduction Human genome projects and high throughput

More information

Changing the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle

Changing the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle Changing the Culture of Cancer Care II Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle Transforming Cancer Therapy Eric Holland Fred Hutchinson Cancer Research Center

More information

Hepatocellular Carcinoma (HCC): What Treatment Modality for Which Tumor?

Hepatocellular Carcinoma (HCC): What Treatment Modality for Which Tumor? K. Rajender Reddy, MD, CG Hepatocellular Carcinoma (HCC): What Treatment Modality for Which Tumor? K. Rajender Reddy, MD, CG Ruimy Family President s Distinguished Professor of Medicine Director of Hepatology

More information

Tratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt

Tratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt Tratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt University Neoadjuvant (preoperative) therapy Surgery Systemic

More information

Supplementary Figure 1: Func8onal Network Analysis of Kinases Significantly Modulated by MERS CoV Infec8on and Conserved Across All Time Points

Supplementary Figure 1: Func8onal Network Analysis of Kinases Significantly Modulated by MERS CoV Infec8on and Conserved Across All Time Points A. B. 8 4 Supplementary Figure : Func8onal Network Analysis of Kinases Significantly Modulated by MERS CoV Infec8on and Conserved Across All Time Points Examined. A) Venn diagram analysis of kinases significantly

More information

Breast Cancer: ASCO Poster Review

Breast Cancer: ASCO Poster Review Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy

More information

Secuenciación masiva: papel en la toma de decisiones

Secuenciación masiva: papel en la toma de decisiones Secuenciación masiva: papel en la toma de decisiones Cancer is a Genetic Disease Development of cancer is driven by the acquisition of somatic genetic alterations: Nonsynonymous point mutations: missense.

More information

Table S1. Demographics of patients and tumor characteristics.

Table S1. Demographics of patients and tumor characteristics. Supplemental Tables for: A Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers Kim Hirshfield et al. Table S1. Demographics of patients and tumor characteristics.

More information

Genomic Medicine: What every pathologist needs to know

Genomic Medicine: What every pathologist needs to know Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and

More information

Exons from 137 genes were targeted for hybrid selection and massively parallel sequencing.

Exons from 137 genes were targeted for hybrid selection and massively parallel sequencing. SUPPLEMENTARY TABLES Supplementary Table 1. Targeted Genes ABL1 ABL2 AKT1 AKT2 AKT3 ALK APC ATM AURKA BCL2 BRAF BRCA1 BRCA2 CCND1 CCNE1 CDC73 CDH1 CDK4 CDK6 CDK8 CDKN1A CDKN2A CEBPA CHEK1 CHEK2 CREBBP

More information

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB

More information

The Center for PERSONALIZED DIAGNOSTICS

The Center for PERSONALIZED DIAGNOSTICS The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)

More information

Diagnostica Molecolare!

Diagnostica Molecolare! Diagnostica Molecolare! Aldo Scarpa Unità Diagnostica Molecolare Azienda Ospedaliera Universitaria Integrata di Verona e ARC-NET Centro di Ricerca Applicata sul Cancro PDTA CARCINOMA POLMONARE - IL PAZIENTE

More information

IMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY

IMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY Madrid, Spain IMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY Dr. JL Rodríguez Peralto NGS Ion Torrent Oncomine Focus Assay - Implementation experience for EGFR mutation detection

More information

What is Precision Medicine?

What is Precision Medicine? Precision Medicine and the Treatment of Cancer Carlos L. Arteaga, MD Center for Cancer Targeted Therapies VICC Breast Cancer Program Vanderbilt-Ingram Cancer Center (VICC) Departments of Medicine and Cancer

More information

Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes

Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes Nature Genetics 47, 106-114 (2015) doi:101038/ng3168 Max Leiserson RECOMB 2015 April

More information

Supplementary Table S1: Primers for DNA sequencing (A), quantification of. relative mrna expression (B), and copy number analysis (C)

Supplementary Table S1: Primers for DNA sequencing (A), quantification of. relative mrna expression (B), and copy number analysis (C) Supplementary Table S1: Primers for DNA sequencing (A), quantification of relative mrna expression (B), and copy number analysis (C) A. DNA sequencing (1-4) Genes Primers Sequence EGFR exon 18 EGFR E18F

More information

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor

More information

Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins

Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins February 3-5, 2016 Lansdowne Resort, Leesburg, VA Molecular

More information

5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff

5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff 5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late

More information

# 1 India s Best Selling Cancer Genomics Test Precision treatment for every Cancer Patient Patient Guide

# 1 India s Best Selling Cancer Genomics Test Precision treatment for every Cancer Patient Patient Guide # 1 India s Best Selling Cancer Genomics Test Precision treatment for every Cancer Patient Patient Guide PositiveSelect is India s widely used Cancer Genomics test with every 8 out of 10 patients opting

More information

SALSA MLPA Probemix P014-B1 Chromosome 8 Lot B and B

SALSA MLPA Probemix P014-B1 Chromosome 8 Lot B and B SALSA MLPA Probemix P014-B1 Chromosome 8 Lot B1-0916 and B1-0713. Copy number changes of the human chromosome 8 are common in many types of tumours. In most cases, losses of 8p sequences and gains of 8q

More information

Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester

Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester dsg6@le.ac.uk CFDNA/CTDNA Circulating-free AS A LIQUID DNA BIOPSY (cfdna) Tumour Biopsy Liquid Biopsy

More information

Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope

Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope National Medical Center Disclosures I have no disclosures

More information

Next generation histopathological diagnosis for precision medicine in solid cancers

Next generation histopathological diagnosis for precision medicine in solid cancers Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics

More information

APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE

APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE AMP COMPANION MEETING SYMPOSIUM AT USCAP 2015 NEXT-GENERATION OF PATHOLOGY: ROLE OF PATHOLOGIST IN NGS-BASED PERSONALIZED MEDICINE APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST

More information

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically

More information

Importancia del patólogo en los tumores de origen desconocido

Importancia del patólogo en los tumores de origen desconocido Importancia del patólogo en los tumores de origen desconocido Dr. Federico Rojo Fundación Jiménez Díaz, Madrid IMIM-Hospital del Mar, Barcelona Cancer unknown primary 3-5 % of diagnosed cancers Variability

More information

Addressing Tumor Molecular Heterogeneity using A Novel Clinical Trial Design - PANGEA

Addressing Tumor Molecular Heterogeneity using A Novel Clinical Trial Design - PANGEA Addressing Tumor Molecular Heterogeneity using A Novel Clinical Trial Design - PANGEA Daniel Catenacci, MD Assistant Professor of Medicine Associate Director GI Oncology Program May 12, 2017 Addressing

More information

Oncomine Focus assay panel and Oncomine Knowledgebase Reporter.

Oncomine Focus assay panel and Oncomine Knowledgebase Reporter. Oncomine Focus assay panel and Oncomine Knowledgebase Reporter. How it can help to identify relevant alteration and early phase trials. Dr Isabelle SOUBEYRAN Dr Emmanuel KHALIFA Molecular Pathology Unit

More information

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs

More information

Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory

Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific

More information

Development of Circulating Tumor DNA

Development of Circulating Tumor DNA Development of Circulating Tumor DNA Title of presentation Arial Bold 30pt in White Biomarkers Secondary title 22pt using Arial Next in White Generation Sequencing Brian Dougherty PhD, MBA Translational

More information

An Integrative Pharmacogenomic Approach Identifies Two-drug. Combination Therapies for Personalized Cancer Medicine

An Integrative Pharmacogenomic Approach Identifies Two-drug. Combination Therapies for Personalized Cancer Medicine An Integrative Pharmacogemic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine Yin Liu 1,2,3, Teng Fei 4,5, Xiaoqi Zheng 6, Myles Brown 4,5, Peng Zhang 7*, X. Shirley

More information

Phosphorylation Site Company Cat #

Phosphorylation Site Company Cat # Supplemental Table 1. Antibodies used for RPPA analysis. Label Protein Phosphorylation Site Company Cat # Used on MDA_CLSS Used on MDA_Pilot 4EBP1 4EBP1 Cell Signaling 9452 No 4EBP1.pS65 4EBP1 S65 Cell

More information

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 8 1.5. Primary Tumour Description... 10 1.6.

More information

Supplementary figures legends

Supplementary figures legends Supplementary Information to Nijmegen Breakage Syndrome fibroblasts and ipscs: cellular models for uncovering diseaseassociated signaling pathways and establishing a screening platform for anti-oxidants

More information

Case Study. Chikako Shimizu, MD Breast and Medical Oncology Division National Cancer Center Hospital

Case Study. Chikako Shimizu, MD Breast and Medical Oncology Division National Cancer Center Hospital Case Study Chikako Shimizu, MD Breast and Medical Oncology Division National Cancer Center Hospital Triplenegative paradox Cortazar P et al. Lancet 2014 Chief Complaints A lump in the right breast Fertility

More information

Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival -- Evidence from TCGA Pan-Cancer Data

Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival -- Evidence from TCGA Pan-Cancer Data Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival -- Evidence from TCGA Pan-Cancer Data Supplementary Materials Xiu Huang, David Stern, and

More information

Accel-Amplicon Panels

Accel-Amplicon Panels Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation

More information

Ginny Li, Christine Vogel, Hyungwon Choi. Supplementary Table 1. Performance evaluation of the linear SVMs across five modification

Ginny Li, Christine Vogel, Hyungwon Choi. Supplementary Table 1. Performance evaluation of the linear SVMs across five modification Electronic Supplementary Material (ESI) for Molecular Omics. This journal is The Royal Society of Chemistry 2018 Supplementary Information for PTMscape: an open source tool to predict generic post-translational

More information

Nature Genetics: doi: /ng Supplementary Figure 1

Nature Genetics: doi: /ng Supplementary Figure 1 Supplementary Figure 1 Genomic alterations detectable in cfdna of EGFR-mutant p.t790m-positive and p.t790m-negative patients. (a-b) Lolliplots of gene level alterations in EGFR-mutant p.t790m mutant positive

More information

ras Multikinase Inhibitor Multikinase Inhibitor 0.1

ras Multikinase Inhibitor Multikinase Inhibitor 0.1 a ras ** * ** * ** ** ** ** un in et m lu Se ib SL G 32 W 7 So 50 ra 74 fe ni b LY W 294 or 0 tm 02 R an ap n a in Ev my er cin ol im BE us Z2 3 En P 5 za I13 st 0 au rin D as SP ati 60 nib C 012 is 5

More information

Breast Cancer RESULT INTERPRETATION THERAPRINT OVERVIEW

Breast Cancer RESULT INTERPRETATION THERAPRINT OVERVIEW Breast Cancer PAGE 1 OF 7 Patient: DOB: Patient #: Gender: Customer Ref.: SPECIMEN Requisition: Collection Date: Date Received: Report Date: Specimen Site: Tumor Origin: Unspecified Breast PHYSICIAN Ordering

More information

Supplemental Information. High-Throughput Microfluidic Labyrinth for the. Label-free Isolation of Circulating Tumor Cells

Supplemental Information. High-Throughput Microfluidic Labyrinth for the. Label-free Isolation of Circulating Tumor Cells Cell Systems, Volume 5 Supplemental Information High-Throughput Microfluidic Labyrinth for the Label-free Isolation of Circulating Tumor Cells Eric Lin, Lianette Rivera-Báez, Shamileh Fouladdel, Hyeun

More information

Dox. R26-rtTA Tyr-CreERT2. any ink/arf, no rtta (n=8) ink/arf +/+ (n=5) Day 0 Day 11 Day 18 Day 28

Dox. R26-rtTA Tyr-CreERT2. any ink/arf, no rtta (n=8) ink/arf +/+ (n=5) Day 0 Day 11 Day 18 Day 28 A 4OHT Dox hraf iip tumors inras ddh 2 O -RT Ink/Arf / Pten l/ l R26-lsl-rtTA Tyr-reERT2 TetO-hRAF V6E Ink/Arf / Pten / R26-rtTA Tyr-reERT2 TetO-hRAF V6E Ink/Arf / Pten / R26-rtTA Tyr-reERT2 TetO-hRAF

More information

Disclosures Genomic testing in lung cancer

Disclosures Genomic testing in lung cancer Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing

More information

Next generation sequencing on FFPE tumor tissues for lung and colorectal carcinoma diagnostics and research Sakari Knuutila

Next generation sequencing on FFPE tumor tissues for lung and colorectal carcinoma diagnostics and research Sakari Knuutila Next generation sequencing on FFPE tumor tissues for lung and colorectal carcinoma diagnostics and research Sakari Knuutila Faculty of Medicine / Haartman Institute / Department of Pathology / Sakari Knuutila

More information

Multi-drug, genetic-marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer

Multi-drug, genetic-marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer Multi-drug, genetic-marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer Sponsor: University of Birmingham Chief Investigator: Gary Middleton Chief Biostatistician:

More information

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran

More information

EXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)

EXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%) Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999

More information

OncoMir Library Cancer Type Target Gene

OncoMir Library Cancer Type Target Gene OncoMir Library Cancer Type Target Gene hsa-let-7a-1 Breast Cancer, Lung Cancer H RAS, HMGA2, CDK6, NRAS hsa-let-7a-2 Breast Cancer, Lung Cancer H RAS, HMGA2, CDK6, NRAS hsa-let-7a-3 Breast Cancer, Lung

More information

Supplementary Information

Supplementary Information Supplementary Information Title: Role of Cytochrome P450 (CYP)1A in Hyperoxic Lung Injury: Analysis of the Transcriptome and Proteome Authors: Krithika Lingappan a, Suman Maity b, Weiwu Jiang a, Lihua

More information

Karl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz

Karl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz Expanding on WHO guideline compliant molecular testing of central nervous system tumors by low density whole genome sequencing. Karl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz

More information

Developments in small cell lung cancer G. Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliates National Cancer Institute Bethesda MD USA

Developments in small cell lung cancer G. Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliates National Cancer Institute Bethesda MD USA Developments in small cell lung cancer G. Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliates National Cancer Institute Bethesda MD USA Geneva April 20, 2012 Neuroendocrine tumors of lung Typical

More information

Provide your cancer patients personalized treatment options with ClariFind

Provide your cancer patients personalized treatment options with ClariFind ONCOLOGY ClariFind employs next-generation sequencing (NGS) for comprehensive genomic profiling of a patient s tumor sample to identify potential clinically actionable targets and associated therapies.

More information

The linking of specific cancer genetic alterations to molecular targeted therapies is driving a new era of personalised medicine

The linking of specific cancer genetic alterations to molecular targeted therapies is driving a new era of personalised medicine The linking of specific cancer genetic alterations to molecular targeted therapies is driving a new era of personalised medicine Oncologica addresses this new era of precision medicine by exploiting state

More information

The mir-199a/brm/egr1 axis is a determinant of anchorage-independent growth in epithelial tumor cell lines

The mir-199a/brm/egr1 axis is a determinant of anchorage-independent growth in epithelial tumor cell lines Supplementary information Supplementary Figure -9 Supplementary Table -4 The mir-99a/brm/egr axis is a determinant of anchorage-independent growth in epithelial tumor cell lines Kazuyoshi Kobayashi, Kouhei

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION doi:10.1038/nature15260 Supplementary Data 1: Gene expression in individual basal/stem, luminal, and luminal progenitor cells. Box plots show expression levels for each gene from the 49-gene differentiation

More information

Therapeutic Resistance to HER2 Targeted Therapies. Neil Spector, M.D Duke Cancer Institute Duke University Medical Center

Therapeutic Resistance to HER2 Targeted Therapies. Neil Spector, M.D Duke Cancer Institute Duke University Medical Center Therapeutic Resistance to HER2 Targeted Therapies Neil Spector, M.D Duke Cancer Institute Duke University Medical Center Relevant Financial Disclosures Millennium/Takeda Pharmaceuticals (consultant, sponsored

More information

S1 Appendix: Figs A G and Table A. b Normal Generalized Fraction 0.075

S1 Appendix: Figs A G and Table A. b Normal Generalized Fraction 0.075 Aiello & Alter (216) PLoS One vol. 11 no. 1 e164546 S1 Appendix A-1 S1 Appendix: Figs A G and Table A a Tumor Generalized Fraction b Normal Generalized Fraction.25.5.75.25.5.75 1 53 4 59 2 58 8 57 3 48

More information

Diagnostic application of SNParrays to brain cancers

Diagnostic application of SNParrays to brain cancers Diagnostic application of SNParrays to brain cancers Adriana Olar 4/17/2018 No disclosures 55 yo M, focal motor seizure T2 T1-post C DIAGNOSIS BRAIN, LEFT FRONTAL LOBE, BIOPSY: - DIFFUSE GLIOMA, OLIGODENDROGLIAL

More information

Clinical molecular profiling of archival tumor tissue and cell-free DNA from patients with Erdheim-Chester disease

Clinical molecular profiling of archival tumor tissue and cell-free DNA from patients with Erdheim-Chester disease ECD International Medical Symposium New York City October 26, 2017 Clinical molecular profiling of archival tumor tissue and cell-free DNA from patients with Erdheim-Chester disease Filip Janku, Eli Diamond,

More information

ACTIVITY 2: EXAMINING CANCER PATIENT DATA

ACTIVITY 2: EXAMINING CANCER PATIENT DATA OVERVIEW Refer to the Overview of Cancer Discovery Activities for Key Concepts and Learning Objectives, Curriculum Connections, and Prior Knowledge, as well as background information, references, and additional

More information

Comparative Effectiveness Research (CER) and Personalized Medicine: Policy, Science, and Business

Comparative Effectiveness Research (CER) and Personalized Medicine: Policy, Science, and Business Comparative Effectiveness Research (CER) and Personalized Medicine: How a comprehensive CER system can support personalized medicine Amy P. Abernethy, MD October 28, 2009 CER in Cancer Care? 2 Friends

More information

Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation

Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation James Chih-Hsin Yang, MD, PhD National Taiwan University Hospital National Taiwan University Cancer Center Taipei, Taiwan

More information

Nature Genetics: doi: /ng Supplementary Figure 1. Mutational signatures in BCC compared to melanoma.

Nature Genetics: doi: /ng Supplementary Figure 1. Mutational signatures in BCC compared to melanoma. Supplementary Figure 1 Mutational signatures in BCC compared to melanoma. (a) The effect of transcription-coupled repair as a function of gene expression in BCC. Tumor type specific gene expression levels

More information

Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders

Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders Richard D. Press, MD, PhD Dept of Pathology Knight Cancer Institute Knight Diagnostic Labs Oregon Health & Science University

More information

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH ) Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and

More information

Identification of key long non-coding RNAs as competing endogenous RNAs for mirna-mrna in lung adenocarcinoma

Identification of key long non-coding RNAs as competing endogenous RNAs for mirna-mrna in lung adenocarcinoma European Review for Medical and Pharmacological Sciences 2016; 20: 2285-2295 Identification of key long non-coding RNAs as competing endogenous RNAs for mirna-mrna in lung adenocarcinoma D.-S. LI, J.-L.

More information

The role of liquid biopsies in the treatment of advanced colon cancer

The role of liquid biopsies in the treatment of advanced colon cancer The role of liquid biopsies in the treatment of advanced colon cancer Clara Montagut Hospital del Mar, Barcelona ESMO CRC Preceptorship Valencia, May 12, 2017 1 ESMO consensus guidelines for the management

More information

Supplementary Figures

Supplementary Figures Supplementary Figures Supplementary Figure 1 Correlation between LKB1 and YAP expression in human lung cancer samples. (a) Representative photos showing LKB1 and YAP immunohistochemical staining in human

More information

Clinical Grade Biomarkers in the Genomic Era Observations & Challenges

Clinical Grade Biomarkers in the Genomic Era Observations & Challenges Clinical Grade Biomarkers in the Genomic Era Observations & Challenges IOM Committee on Policy Issues in the Clinical Development & Use of Biomarkers for Molecularly Targeted Therapies March 31-April 1,

More information

Oncology Update: The 10 Most Talked About Breast Cancer Topics of The Top 10 10/24/2013. The Awareness Debate

Oncology Update: The 10 Most Talked About Breast Cancer Topics of The Top 10 10/24/2013. The Awareness Debate Oncology Update: The 10 Most Talked About Breast Cancer Topics of 2013 Michaela Tsai, MD Martha Bacon Stimpson Chair of Breast Oncology Virginia Piper Cancer Institute Minnesota Oncology The Top 10 1.

More information

Supplementary Figure 1. Cytoscape bioinformatics toolset was used to create the network of protein-protein interactions between the product of each

Supplementary Figure 1. Cytoscape bioinformatics toolset was used to create the network of protein-protein interactions between the product of each Supplementary Figure 1. Cytoscape bioinformatics toolset was used to create the network of protein-protein interactions between the product of each mutated gene and the panel of 125 cancer-driving genes

More information

SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length.

SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length. SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length. This SALSA probemix is for basic research only! This

More information

Supplementary Figure 1: Comparison of acgh-based and expression-based CNA analysis of tumors from breast cancer GEMMs.

Supplementary Figure 1: Comparison of acgh-based and expression-based CNA analysis of tumors from breast cancer GEMMs. Supplementary Figure 1: Comparison of acgh-based and expression-based CNA analysis of tumors from breast cancer GEMMs. (a) CNA analysis of expression microarray data obtained from 15 tumors in the SV40Tag

More information

Out-Patient Billing CPT Codes

Out-Patient Billing CPT Codes Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB

More information

Webinar Series. Characterizing cancers from liquid biopsies and FFPE samples: The rise of targeted sequencing panels. Participating experts

Webinar Series. Characterizing cancers from liquid biopsies and FFPE samples: The rise of targeted sequencing panels. Participating experts Characterizing cancers from liquid biopsies and FFPE samples: The rise of targeted sequencing panels April 13, 2016 Webinar Series Brought to you by the Science/ AAAS Custom Publishing Office Participating

More information

A homologous mapping method for threedimensional reconstruction of protein networks reveals disease-associated mutations

A homologous mapping method for threedimensional reconstruction of protein networks reveals disease-associated mutations Huang et al. BMC Systems Biology 2018, 12(Suppl 2):13 https://doi.org/10.1186/s12918-018-0537-2 RESEARCH A homologous mapping method for threedimensional reconstruction of protein networks reveals disease-associated

More information

Expanded View Figures

Expanded View Figures Molecular Systems iology Tumor CNs reflect metabolic selection Nicholas Graham et al Expanded View Figures Human primary tumors CN CN characterization by unsupervised PC Human Signature Human Signature

More information

EPIGENETIC RE-EXPRESSION OF HIF-2α SUPPRESSES SOFT TISSUE SARCOMA GROWTH

EPIGENETIC RE-EXPRESSION OF HIF-2α SUPPRESSES SOFT TISSUE SARCOMA GROWTH EPIGENETIC RE-EXPRESSION OF HIF-2α SUPPRESSES SOFT TISSUE SARCOMA GROWTH Supplementary Figure 1. Supplementary Figure 1. Characterization of KP and KPH2 autochthonous UPS tumors. a) Genotyping of KPH2

More information